M. Pairish

发表

Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK).

J. Christensen, B. Mroczkowski, L. Funk, 2011, Journal of medicinal chemistry.

Structure-based design, SAR analysis and antitumor activity of PI3K/mTOR dual inhibitors from 4-methylpyridopyrimidinone series.

M. Pairish, R. Kania, S. Bagrodia, 2013, Bioorganic & medicinal chemistry letters.

Design of oxobenzimidazoles and oxindoles as novel androgen receptor antagonists.

A. Fanjul, M. Pairish, Liming Dong, 2012, Bioorganic & medicinal chemistry letters.

Structural modifications of a 3-methoxy-2-aminopyridine compound to reduce potential for mutagenicity and time-dependent drug-drug interaction.

D. Bouzida, M. Pairish, S. Yamazaki, 2012, Bioorganic & medicinal chemistry letters.

The Antibody Registry: ten years of registering antibodies

M. Martone, J. Grethe, A. Bandrowski, 2022, Nucleic Acids Res..

Discovery of a novel class of exquisitely selective mesenchymal-epithelial transition factor (c-MET) protein kinase inhibitors and identification of the clinical candidate 2-(4-(1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol (PF-04217903) for the treatment of

J. Christensen, J. Cui, M. Tran-Dube, 2012, Journal of medicinal chemistry.

Artificial β-sheets

J. Nowick, M. Pairish, Eric M. Smith, 1996 .

Design, Synthesis, and Study of Artificial β‐Sheets

A. J. Shaka, J. Ziller, J. Nowick, 1997 .

An Extended β-Strand Mimic for a Larger Artificial β-Sheet

J. Ziller, J. Nowick, M. Pairish, 1997 .

Discovery of N-((3R,4R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFR.

Paolo Vicini, Deepak Dalvie, Chengyi Zhang, 2017, Journal of medicinal chemistry.

Structure-Based Drug Design and Synthesis of PI3Kα-Selective Inhibitor (PF-06843195).

Ping Chen, Hong Shen, M. Pairish, 2020, Journal of medicinal chemistry.

Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants.

Deepak Dalvie, Michael Zientek, Rose Ann Ferre, 2016, Journal of medicinal chemistry.

Discovery of 3-aryloxy-lactam analogs as potent androgen receptor full antagonists for treating castration resistant prostate cancer.

A. Fanjul, M. Pairish, S. Greasley, 2012, Bioorganic & medicinal chemistry letters.

Discovery of aryloxy tetramethylcyclobutanes as novel androgen receptor antagonists.

M. Gleave, A. Zoubeidi, A. Fanjul, 2011, Journal of medicinal chemistry.

Systematic structure modifications of imidazo[1,2-a]pyrimidine to reduce metabolism mediated by aldehyde oxidase (AO).

M. Pairish, Qiyue Hu, Ying Jiang, 2011, Journal of medicinal chemistry.

Discovery of 2-((1H-benzo[d]imidazol-1-yl)methyl)-4H-pyrido[1,2-a]pyrimidin-4-ones as novel PKM2 activators.

M. Hickey, M. Pairish, S. Greasley, 2013, Bioorganic & medicinal chemistry letters.

Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants.

K. Gajiwala, N. Sach, Sherry L. Niessen, 2016, Journal of medicinal chemistry.